10-K: Acro Biomedical Reports No Revenue, Significant Losses

Acro Biomedical Co., Ltd. filed its annual report for 2023, revealing no revenue, substantial net losses, and significant going concern doubts.

Summary

• No revenue was generated in 2023 or subsequent to December 31, 2023, through the filing date of July 18, 2025.
• A net loss of $8,807,573 was incurred for the year ended December 31, 2023, following a $15,871,443 net loss in 2022.
• Cash balance stood at a minimal $376 as of December 31, 2023.
• Research and development efforts for a cordyceps-based chicken feed failed to produce a marketable product and ceased in August 2023.
• The company operates with a single part-time, unpaid employee, CEO Pao-Chi Chu, who also serves as CFO, President, Secretary, and sole director.
• Common stock is traded on the OTC Market Group's Expert Market, which lacks market makers and restricts public viewing of quotes, severely limiting liquidity.
• The company is delinquent in multiple SEC filings, including quarterly reports for Q1, Q2, Q3 2024 and Q1 2025, and the annual report for 2024.
• A 'going concern' audit opinion was issued, raising substantial doubt about the company's ability to continue operations.

Sentiment

Score: 1

Explanation: The company reported no revenue, substantial losses, minimal cash, failed R&D, severe going concern doubts, and is delinquent in SEC filings, indicating a critical financial and operational state with extremely high risk.

Positives

• Deferred stock compensation for consultants was fully amortized by December 31, 2023, eliminating this expense going forward.
• Advances from a minority stockholder and the CEO continue to provide minimal funding for operations.

Negatives

• No revenue generated in 2023 or subsequent to December 31, 2023.
• Net loss of $8.8 million in 2023 and $15.9 million in 2022.
• Cash balance of only $376 at December 31, 2023.
• Negative cash flow from operations in both 2023 ($15,446) and 2022 ($147,481).
• $480,000 of accounts receivable from 2022 sales were deemed uncollectible and written off in 2023.
• Research and development efforts for a cordyceps-based chicken feed failed to produce a marketable product and have ceased.
• Dependent on a single part-time, unpaid CEO for all operations, sales, and R&D direction.
• Common stock trades on the OTC Expert Market, lacking market makers and public quotes, severely limiting liquidity and ability to raise capital.
• Significant doubt about the company's ability to continue as a going concern.
• Delinquent in multiple SEC filings (Q1, Q2, Q3 2024, Q1 2025, and 2024 Annual Report).
• Lack of effective disclosure controls and internal controls over financial reporting due to limited staff, lack of segregation of duties, and reliance on external services.
• No full-time chief financial officer; the CEO (without an accounting background) acts as CFO.
• No independent directors, leading to a lack of checks and balances.
• Historical revenue was highly concentrated (two customers accounted for 100% of 2022 revenue and 91.7% of 2021 revenue).
• Business was impacted by political instability in Hong Kong and the aftereffects of China's COVID-19 restrictions on customer sales and ability to pay.
• No product liability insurance.
• No patents or other intellectual property rights.

Risks

• Inability to recommence business, generate revenue, or operate profitably.
• Uncertainty regarding future product development efforts.
• Inability to develop and implement successful marketing programs or establish a marketing organization.
• Uncertainty about the market size and demand for proposed products in the United States.
• Challenges in satisfying chicken farmers and distributors about product safety, cost-effectiveness, and negotiating distribution agreements.
• Inability to obtain significant funding, especially with common stock on the OTC Expert Market.
• Difficulty in developing products attractive to consumers in China and Hong Kong.
• Inability to obtain necessary regulatory approvals and comply with requirements for marketing and selling products.
• Dependence on a small number of customers and inability to develop a broader customer base.
• Inability to collect accounts receivables.
• Inability to obtain products from suppliers on reasonable terms and in a timely manner.
• Inability to identify, hire, and retain qualified personnel.
• Liability from adverse effects or product recalls related to products sold.
• Inability to protect intellectual property or defend against infringement claims.
• Impact of current and future economic and political conditions, including inflation and supply chain issues.
• Lack of an active trading market for common stock on the OTC Expert Market, making it difficult to buy or sell shares.
• Potential for significant stock price volatility due to low public float and lack of trading volume.
• Common stock being a 'penny stock' if a market develops, subject to SEC rules that reduce trading activity.
• Ineffective internal controls over financial reporting and disclosure controls.
• Lack of a full-time chief financial officer with an accounting background.
• Absence of independent directors and checks and balances on the CEO.
• Failure to file timely SEC reports, affecting market and value of common stock.
• Difficulty for investors to enforce federal securities laws against the sole director/officer located outside the United States (Taiwan).
• Dilution of net tangible book value if equity or convertible debt securities are issued for capital raises.
• CEO's significant stock ownership (49.97%) gives him power to elect all directors and approve major corporate actions.
• No intention to pay cash dividends in the foreseeable future.

Future Outlook

The company intends to recommence operations but cannot assure success in developing or marketing products. It may seek to raise funds through equity or related-party loans, anticipating significant dilution for stockholders. Marketing and other expenses are expected without guaranteed revenue generation. The common stock is expected to remain on the Expert Market as long as SEC filings are delinquent.

Management Comments

• Our business plan is in the preliminary stages, and we will require significant funding to implement our business plan, with no assurance that we can or will be successful in developing and implementing our business plan.
• If we are not able to implement our business plan, our business may be materially impaired.
• We have no plans to recommence the development effort for a cordyceps-based chicken feed, although we may seek to recommence this development effort or seek to develop another product.
• Although we intend to recommence our operations, we cannot give any assurance that we will be successful in these efforts.
• We are continuing to rely on advances from the minority stockholder.
• We expect to adopt a code [of ethics] as we develop our business.

Industry Context

Acro Biomedical operates in the highly competitive nutritional products and dietary supplements market, specifically focusing on cordyceps. This market includes many larger, better-capitalized competitors. The niche market for cordyceps in chicken feed is considered small due to high costs. The company's historical reliance on customers in China and Hong Kong makes it vulnerable to economic and political conditions in those regions, such as the aftereffects of China's Zero-COVID policy and Hong Kong's political instability. If the company expands to the U.S., it will be subject to FDA regulations for dietary supplements.

Comparison to Industry Standards

• The company's financial performance, with no revenue and significant losses, is critically below industry standards for a publicly traded entity.
• Operating with a single part-time, unpaid CEO and no other employees is highly unusual and unsustainable for a public company, contrasting sharply with typical corporate structures.
• The failure of significant R&D efforts to yield a marketable product, despite substantial stock-based compensation, indicates a severe lack of operational effectiveness compared to successful biotech or supplement developers.
• Trading on the OTC Expert Market signifies severe financial distress and non-compliance, placing the company far outside the norms of reputable public market participation.
• High customer concentration (100% from two customers in 2022) represents a significant vulnerability, unlike diversified industry players who mitigate such risks.
• The identified material weaknesses in internal controls and lack of segregation of duties are fundamental governance failures, falling far short of acceptable standards for public companies.

Management Changes

Corporate Governance

Related Party Transactions

• Owed $1,100 to CEO Pao-Chi Chu for non-interest-bearing advances as of December 31, 2023, due on demand.
• Owed $87,696 to a minority stockholder for non-interest-bearing advances as of December 31, 2023, due on demand.
• A minority stockholder advanced $9,970 in 2023 and $55,000 in 2022, and paid expenses of $3,085 in 2022 on behalf of the company.
• Imputed interest at 4% on minority stockholder advances amounted to $3,206 in 2023 and $1,706 in 2022.
• CEO Pao-Chi Chu controls Mucho Biotech Co., Ltd., Mucho Furich Co., Ltd., and Mucho Biomedical Co., Ltd., companies engaged in cordyceps applications, creating potential conflicts of interest in time and resource allocation.

Stakeholder Impact

• Shareholders face significant dilution risk from potential capital raises, no active trading market for common stock, high volatility risk, and potential loss of entire investment due to the company's critical financial state and Expert Market listing.
• Employees (currently only the CEO) are unpaid, and the company's ability to attract and retain qualified personnel is severely hampered by its financial condition.
• Historical customers were impacted by political instability and COVID-19, leading to significant uncollectible accounts, and the future customer base remains uncertain.
• Suppliers face risks due to the company's lack of long-term agreements and potential for supply difficulties or increased costs, with no assurance of timely payment.
• Creditors, primarily related parties, are providing essential advances, but the company's ability to repay other creditors is highly questionable given its lack of revenue and minimal cash.

Next Steps

• Recommence operations, though success is not assured.
• Seek to develop new products or recommence cordyceps-based chicken feed development.
• Seek to raise funds in the equity market or through loans from related parties.
• Hire qualified sales, marketing, R&D, and administrative personnel if funds become available.
• Develop and implement effective internal controls over financial reporting if financial condition improves and personnel are hired.
• Adopt a code of ethics.

Key Dates

Recommendation

The company is in a state of severe financial distress, reporting no revenue, substantial losses, and a critically low cash balance. Its R&D efforts have failed, it operates with minimal personnel, and its stock is illiquid on the OTC Expert Market. The 'going concern' audit opinion, coupled with multiple delinquent SEC filings and significant internal control weaknesses, indicates an extremely high risk of business failure. There are no discernible positive catalysts, and the risks of further capital loss are paramount for investors.

Keywords

Acro Biomedical, SEC filing, 10-K, annual report, nutritional products, cordyceps, dietary supplements, financial performance, going concern, OTC Expert Market, stock-based compensation, related party transactions, corporate governance, risk factors, Pao-Chi Chu, financial reporting, internal controls, market volatility, capital raise